TWYNEO® (tretinoin & benzoyl peroxide) cream
Acne vulgaris
Key Facts
About Sol-Gel Technologies
Sol-Gel Technologies leverages its patented silica-based microencapsulation technology to create novel topical dermatological products with improved efficacy, stability, and patient tolerability. The company transitioned to a commercial-stage entity with the U.S. launch of TWYNEO® in 2022 and is advancing a pipeline targeting acne, rosacea, and other dermatological conditions. Its strategy combines proprietary development with strategic partnerships, such as the license agreement with Galderma for Epsolay® and TWYNEO®, to maximize the reach of its innovative treatments.
View full company profileTherapeutic Areas
Other Acne vulgaris Drugs
| Drug | Company | Phase |
|---|---|---|
| Epiduo/Epiduo Forte | Galderma Group | Approved |
| CB-03-01 (Breezula®) | Cosmo Pharmaceuticals | Phase 3 |
| SGT-310 (cannabidiol) gel | Sol-Gel Technologies | Preclinical |
| SGT-510 (tapinarof) cream | Sol-Gel Technologies | Preclinical |
| Fabior (tazarotene) Foam | Mayne Pharma Group | Approved |
| Amzeeq | Vyne Therapeutics | Approved |